Core Viewpoint - The stock of HeFu China has surged over 256.29% in a short period, prompting the company to announce a trading suspension for verification due to significant price volatility and potential irrational market behavior [1][3] Group 1: Stock Performance - HeFu China's stock experienced a remarkable increase, with 12 out of 14 trading days closing at the daily limit price from October 28 to November 14, 2025 [1] - The stock's trading volume showed significant fluctuations, with a turnover rate reaching as high as 28.48% on November 14, 2025 [1] Group 2: Company Announcements - The company has indicated that it will suspend trading starting November 17, 2025, for no more than three trading days to conduct a verification process [1] - HeFu China has confirmed that there are no undisclosed significant matters, such as major asset restructuring or strategic investments, that could affect its stock performance [3] Group 3: Financial Performance - According to the third-quarter report, HeFu China reported a net loss of 5.048 million yuan, a decline of 225.26% compared to the same period last year [3] - The decrease in profit is attributed to changes in the domestic macroeconomic environment and price reductions due to centralized procurement policies in the medical industry [3]